Argent Biopharma Ltd · ASX:RGT
Argent Biopharma — Investor Presentation (February 2021)
27 slides from Argent Biopharma's investor presentation, Feb 2, 2021
Slide 1: Leading The Way in Phytocannabinoid Derived Medicines
Leading The Way in Phytocannabinoid Derived Medicines Investor Presentation 2 February 2021
Slide 2: Corporate Overview
Corporate Overview MGC Pharmaceuticals Ltd (ASX: MXC) is a European based Shareholder Breakdown bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally. The Company’s core business strategy is to 7% develop and supply high quality p
Slide 3: Company Mission
Company Mission “To Build an Innovative, Vertically Integrated bio-pharma company providing Standardised, Affordable Phytocannabinoid Derived Medicines of the Highest Regulatory Compliance for Targeted global markets and patients” MGC Pharma Total Global Unit Sales – Moving towards break even of 5,0
Slide 4: Board of Directors
Board of Directors Highly qualified team with over 15 years of relevant experience Roby Zomer Brett Mitchell Nativ Segev Dr. Stephen Parker Dr. Ross Walker Evan Hayes Managing Director, CEO & Co. Executive Chairman & Co. Non- Executive Director & Non- Executive Director & Non- Executive Director & N
Slide 5: Key Clinical and Operational Management
Key Clinical and Operational Management Leading experts in the medical cannabis space with unparalleled expertise Nicole Godresse Dr. Jonathan Grunfeld Prof. Emeritus Uri Kramer Dr. Nadya Lisovoder Amir Polak Global Chief Sales Officer Head of Oncology and Palliative Product Head of Neurology Produc
Slide 6: Company Highlights
Company Highlights MGC Pharma is a European based, vertically integrated bio-pharma company supplying EU-GMP Phytocannabinoid derived products to patients, with increasing product sales in Australia, NZ, UK, Ireland and Brazil through special access schemes, and new key markets opening in EU and Isr
Slide 7: Company Strategy
Company Strategy Development and commercialisation of Phytocannabinoid derived products through a vertically integrated, core IP value chain delivering a “Nature to Medicine” business strategy with global distribution capability in place Extraction & Clinical Product Genetics Distribution Isolation
Slide 8: Products
Products MGC Pharma | Company Presentation | January 2021 8
Slide 9: Phytomedicines − Investigational Products
Phytomedicines − Investigational Products MGC’s Phytomedicines are Plant based products proceeding through clinical trails to obtain marketing authorization, which will allow doctors around the world to prescribe a product with accurate claim to treat symptoms These investigational products allow MG
Slide 10: MGC Phytotherapeutics Products
MGC Phytotherapeutics Products Line of EU-GMP certified phytotherapeautic products currently available for prescription by medical professionals under special access schemes The MGC MP brand of products are non-IMP, providing medical professionals a range of products to prescribe as they see best su
Slide 11: Product Research & Development
Product Research & Development MGC Pharma | Company Presentation | January 2021 11
Slide 12: Clinical R&D – Key Products Trials
Clinical R&D – Key Products Trials 3 research areas based on medical experience and large data collections. MGC Pharma has commenced the following clinical trials for three of its key Phytomedicine products CannEpil®, CogniCann® and ArtemiCTM Research Areas Key Products Neurology Phase IIb Clinical
Slide 13: CannEpil®
CannEpil® CannEpil® is a Phytocannabinoid derived IMP used as a treatment for refractory epilepsy Neurological Disorders • Available to prescribe in Australia and UK as Epilepsy an Investigational Medicinal Product through early patient access schemes Target Market: • CannEpil® is an oral oil soluti
Slide 14: CogniCann®
CogniCann® CogniCann® is MGC Pharma’s second Phytocannabinoid derived IMP designed to improve dementia Neurological and Alzheimer’s disease patients quality of life Disorders Dementia • Available to prescribe in Australia as an Investigational Medicinal Product through Target Market: Early Patient A
Slide 15: ArtemiC – Successful results from COVID-19 Phase II Clinical Trial
ArtemiCTM – Successful results from COVID-19 Phase II Clinical Trial ArtemiCTM is a natural water-soluble food supplement containing four natural based ingredients consisting of Artemisinin, Curcumin, Boswellia serrata, and Vitamin C • ArtemiCTM uses the MyCell EnhancedTM delivery system technology,
Slide 16: ArtemiC Clinical Trial Results
ArtemiCTM Clinical Trial Results 100% success in “Time to clinical improvement” based on the national Early Warning Score 2 (NEWS2) of </=2 Maintained for 24 Hours in comparison to routine treatment NEWS Score 2 is the National Early Warning Score (NEWS), by the FDA, which advocates a system to stan
Slide 17: R&D – Preclinical
R&D – Preclinical Developing medicines that leverage its proprietary medical cannabis formula through clinical trials in Israel, Europe and Australia. Enable future medical product sales across the EU, Australia and other geographies, following the legal and regulatory approvals Neurological CepaCan
Slide 18: Manufacturing, Distribution and Patient Access
Manufacturing, Distribution and Patient Access MGC Pharma | Company Presentation | January 2021 18
Slide 19: EU-GMP Manufacturing Facility
EU-GMP Manufacturing Facility Slovenian EU-GMP certified facility has the capacity to manufacture up to 12,000 prescription products per month – 3 year GMP license granted. Based on 5,000 units per month, the Company would be at operating cashflow breakeven, excluding Research costs. Malta facility
Slide 20: Key Global Distribution Partners
Key Global Distribution Partners Extensive network in place providing access to hospitals, pharmacies and research institutions around the world – Lenis is the Company’s wholesaler/exporter to all distributors globally and is also a direct distributor to key European markets. The Acquisition of Medi
Slide 21: Key Distribution Partners and Patient Access
Key Distribution Partners and Patient Access MGC Pharma completed the acquisition of 100% of the operating telehealth clinic - business assets, data and IP of Medicinal Cannabis Clinics in November 2020, providing an additional operating platform with import and distribution capacity Supply and dist
Slide 22: Medicinal Cannabis Clinics – the Next Phase of Growth in Australia
Medicinal Cannabis Clinics – the Next Phase of Growth in Australia In November 2020, MGC Pharma completed the acquisition of 100% of the operating telehealth clinic - business assets, data and IP of Medicinal Cannabis Clinics (MCC) About MCC Strategic synergies providing expedited commercial growth
Slide 23: Investment Proposition
Investment Proposition Fully Integrated Model: Research → Product Development → Commercialise Built on Decades of Experience Focussed Operations Strategically Located Technical team of globally recognised Core divisions: Operational bases close to key markets scientists and doctors • Research and De
Slide 24: Proposed Placing and Use of Funds
Proposed Placing and Use of Funds The Company has applied to have its securities traded on the Standard Listing Segment of the London Stock Exchange in addition to its current listing on the ASX. In conjunction with admission to the London market, there is a proposed Placing of new equity to raise a
Slide 25: Disclaimer
Disclaimer . IMPORTANT: You must read the following disclaimer before continuing. The following disclaimer applies to the following presentation and you are therefore advised to read this disclaimer carefully before reading, assessing or making any other use of the presentation. In accessing the pre
Slide 26: Disclaimer continued
Disclaimer continued Neither Turner Pope, MGC, nor their respective related bodies corporate, directors, officers, partners, their advisers, agents and/or employees accept any responsibility or liability to you or to any other person or entity arising out of this Presentation including pursuant to t
Slide 27: Contact details
https://mgcpharma.com.au/ @mgcpharamaceuticals @MGC_Pharma MGC Pharmaceuticals Ltd Australian PR/IR - Media and Capital Partners Rod Hinchcliffe +61 412 277 377 rod.hinchcliffe@mcpartners.com.au UK PR – Tavistock Charles Vivian +44 20 7920 3150 Charles.Vivian@tavistock.co.uk MGC Pharma | Company Pre
Argent Biopharma — Investor Presentation (February 2021) on 6ix